Loading...
•
Mar 31, 2021
Arrowhead Pharmaceuticals Q2 2021 Earnings Report
Arrowhead Pharmaceuticals reported financial results for the fiscal second quarter ended March 31, 2021.
Key Takeaways
Arrowhead Pharmaceuticals announced its fiscal second quarter results with revenue of $32.811 million and a net loss of $26.818 million, resulting in a loss per share of $0.26.
Announced positive interim 48-week liver biopsy results from the AROAAT2002 study.
Consistent and substantial reduction in intra-hepatic mutant AAT protein (Z-AAT), both Z-AAT monomer and Z-AAT polymer.
Submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for a Phase 2b dose-finding clinical study of ARO-ANG3.
Submitted an IND to the FDA for a Phase 2b dose-finding clinical study of ARO-APOC3.
Forward Guidance
No specific forward guidance was found in the provided document.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...